It has been argued that routine imaging is not cost-effective because of a low detection rate, but studies have previously assumed that all patients should have routine imaging, without first selecting those with high biological risk.[43,60,61] A 2014 study modeled with data from 1992 to 2007 at MD Anderson Cancer Center, which was limited to the identification of surgically resectable recurrences,[60] could now be expanded, given the availability of better systemic treatments. More recently, a prospective study in 290 stage IIB–IIIC patients showed that biannual CT scan and brain MRI for the first 5 years after diagnosis identified 84% of distant metastases, primarily in an asymptomatic state.[52] In a cost analysis of the same cohort, biannual CT scan was found to be cost-effective for stage IIB patients up to 3 years and up to 5 years for stage IIC/III patients based on incremental cost-effectiveness ratios.[62] Another consideration with respect to the cost/benefit ratio of early detection–identified treatment-amenable disease is that end-of-life care has been estimated to constitute a substantial proportion of melanoma-related healthcare costs.[63] Given the long-term response durability with newer therapies and the interaction of lower tumor burden with response, the paradigm of what is considered cost-effective care may be shifting and is deserving of additional studies.
Conclusions and Future Perspectives
In the era of modern immunotherapy and targeted therapy, patients have much greater odds of a successful outcome for the treatment of their disease. Median survival times are vastly improved over those of prior decades, and clinical trials offer great hope for even further therapeutic advances. Durable responses have been observed with targeted therapy and immunotherapy.[24,64] Of patients who completed 2 years of pembrolizumab, 86% had durable responses lasting almost 2 years after treatment discontinuation.[64] Despite these significant advances, however, many patients still succumb to metastatic disease. A greater understanding of the role of tumor burden as a modulating factor in the efficacy of antimelanoma therapy is important. It is apparent that the current available treatments have greater odds of efficacy in patients with a smaller, more-limited disease burden (Table). Whereas emerging evidence suggests that the balance between tumor burden and the amount of T-cell reinvigoration plays a role in the anti–PD-1 response, the mechanistic relationship between tumor burden and response to other treatments remains to be fully elucidated. Additionally, a standardized means of measuring and reporting tumor burden could be useful to further prospectively analyze the predictive role of tumor burden and to improve its utility across studies and in the clinic. Expansion of the role of molecular testing for risk stratification may help identify subgroups of patients at highest risk for relapse and in need of higher-intensity surveillance, sparing many low-risk patients the need for surveillance. Taken together, the existing evidence on tumor burden and treatment outcomes supports further exploration of tumor burden as a predictive factor for future clinical trials and potential consideration in clinical practice when evaluating therapy choice and discussing response expectations with individual patients.
Financial Disclosure: Dr. Carvajal has been a consultant to AstraZeneca, Bristol-Myers Squibb, Iconic Therapeutics, Janssen, Merck, Novartis, and Roche/Genentech; and an advisory board member for Aura Biosciences, Castle Biosciences, Chimeron, and Rgenix. Dr. Poklepovic has been a consultant to Bristol-Myers Squibb and is an advisory board member for Castle Biosciences. Kristen Meldi Plasseraud, PhD, an employee and option holder at Castle Biosciences, Inc, provided writing support for this review.
References:
1. Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93:1042-6.
2. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011;196:468-73.
3. Gupta S, Bedikian AY, Ahrar J, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol. 2010;33:474-80.
4. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100:122-9.
5. Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol. 2010;74:e38-44.
6. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589-95.
7. Iacovelli R, Lanoy E, Albiges L, Escudier B. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int. 2012;110:1747-53.
8. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:1821-8.
9. Fei F, Messina C, Slaets L, et al. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. Eur J Cancer. 2015;51:301-9.
10. Montagna E, Bagnardi V, Rotmensz N, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124:689-99.
11. Gobbi PG, Valentino F, Bassi E, et al. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2011;11:396-402.
12. Jagannath S, Velasquez WS, Tucker SL, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol. 1986;4:859-65.
13. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009;86:167-74.
14. Akyuz M, Yazici P, Dural C, et al. Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc. 2016;30:2567-71.
15. Abbott AM, Doepker MP, Kim Y, et al. Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol. 2018;41:747-53.
16. Warner AB, Postow MA. Bigger is not always better: tumor size and prognosis in advanced melanoma. Clin Cancer Res. 2018 Jun 14. [Epub ahead of print]
17. Gershenwald JD, Scoyler RA, Hesss KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;6:472-92.
18. Steinman J, Ariyan C, Rafferty B, Brady MS. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. J Surg Oncol. 2014;109:405-9.
19. Alexander HR Jr, Fraker DL, Bartlett DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol. 2010;28:114-8.
20. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780-8.
21. Kaufman H, Amatruda T, Nemunaitis JJ, et al. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). J Clin Oncol. 2015;33:9074.
22. Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28:1631-9.
23. Schadendorf D, Long GV, Stroiakovski D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017;82:45-55.
24. Long GV, Eroglu Z, Infante J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol. 2018;36:667-73.
25. Menzies AM, Haydu LE, Carlino MS, et al. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One. 2014;9:e85004.
26. Sefidgar M, Soltani M, Raahemifar K, et al. Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors. J Biol Eng. 2014;8:12.
27. Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014;2:40.
28. Lyle MK, Lee JHJ, Menzies AM, et al. Lesion-specific patterns of response and progression with anti-PD1 treatment in metastatic melanoma (MM). J Clin Oncol. 2014;32:9077.
29. Khoja L, Kibiro M, Metser U, et al. Patterns of response to anti-PD-1 treatment: An exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer. 2016;115:1186-92.
30. Joseph RW, Elassaiss-Schaap J, Kefford RF, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res. 2018 Apr. 23. [Epub ahead of print]
31. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600-9.
32. Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668-74.
33. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-5.
34. Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016;55:111-21.
35. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813-23.
36. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-55.
37. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-30.
38. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-35.
39. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-801.
40. Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009;16:941-7.
41. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703-5.
42. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995;221:566-9; discussion 569-71.
43. Bassères N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology. 1995;191:199-203.
44. Garbe C, Paul A, Kohler-SpÓth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520-9.
45. Berger AC, Ollila DW, Christopher A, et al. Patient symptoms are the most frequent indicators of recurrence in patients with American Joint Committee on Cancer stage II melanoma. J Am Coll Surg. 2017;224:652-9.
46. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042-7.
47. Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24:939-46.
48. Damude S, Hoekstra-Weebers JE, Francken AB, et al. The MELFO-Study: Prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients-results after 1 year. Ann Surg Oncol. 2016;23:2762-71.
49. Leon-Ferre RA, Kottschade LA, Block MS, et al. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017;27:335-41.
50. Leiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res. 2010;20:240-6.
51. Park TS, Phan GQ, Yang JC, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol. 2017;24:947-51.
52. Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75:516-24.
53. Madu MF, Timmerman P, Wouters MWJM, et al. PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. Melanoma Res. 2017;27:251-7.
54. Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (< 1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol. 2015;135:1190-3.
55. Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol. 2010;130:793-7.
56. Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017;10:152.
57. Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18:130.
58. Schuitevoerder D, Heath M, Cook RW, et al. Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging. J Drugs Dermatol. 2018;17:196-9.
59. Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32:1599-604.
60. Rueth NM, Xing Y, Chiang YJ, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014;259:1215-22.
61. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients–monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151-7.
62. Podlipnik S, Moreno-Ramirez D, Carrera C, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma. Br J Dermatol. 2018 Jun 7. [Epub ahead of print]
63. Guy GP Jr, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: a systematic review of the literature, 1990-2011. Am J Prev Med. 2012;43:537-45.
64. Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. J Clin Oncol. 2018;36:9503.
65. Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19:510-20.